Interviews

Remibrutinib is the first oral advanced therapy for adults with chronic spontaneous urticaria (CSU) who remain uncontrolled on high-dose second-generation antihistamines.

Careful history, adherence support, and proper medication technique are central to diagnosing and managing chronic cough in children.

Social determinants of health and environmental exposures during extreme weather events worsen asthma outcomes.

Managing high-cost oncology therapies requires extensive cross-functional coordination, with pharmacists playing a central role.

Comprehensive prevention and cardiometabolic risk control in prediabetes can reduce long-term complications, improve survival, and lower health system burden.

Oncology pharmacists can advocate and communicate clearly to boost recognition, strengthen care teams, and improve cancer treatment outcomes.

Oncology pharmacists can share advocacy tips, craft elevator pitches, and use virtual Capitol Hill days to boost patient access and cancer care.

Preventing progression from prediabetes to type 2 diabetes improves patient outcomes while substantially reducing health system greenhouse gas emissions.

Pharmacists boost late-season flu, COVID-19, and RSV vaccination with coadministration guidance, fatigue-fighting messaging, and community access strategies.

The FDA accepts Moderna’s mRNA flu vaccine filing, targeting adults 50 years and older, with an accelerated path for older adults and a 2026 decision deadline.

Anne Cassity details the National Community Pharmacists Association's (NCPA's) next pharmacy benefit manager (PBM) reform priorities, focusing on fair pharmacy reimbursement and congressional scrutiny of health care consolidation and vertical integration.

Derek Webb and Dennis Williams outline practical, patient-centered strategies pharmacists can use to personalize OTC allergy recommendations, explain nondrowsy antihistamines clearly, and deliver efficient counseling in busy community settings.

Craig Beavers, PharmD, explores new phase 3 evidence on factor XIa inhibitors for secondary stroke prevention, highlighting OCEANIC-STROKE results, safety, and patient selection.

Joseph Saseen, PharmD, explains how population health strategies and team-based care create new opportunities for pharmacists to identify lipid treatment gaps and lead evidence-based ASCVD prevention.

Anne Cassity explains how Medicare Part D’s move to flat PBM service fees in 2028 may reduce incentives for high-cost formulary placement and support more cost-conscious medication decisions.

Collaborative practice agreements let pharmacists speed multiple sclerosis therapy starts, manage labs, and boost adherence—easing provider workload.

Joseph Saseen, PharmD, highlights how pharmacists can close treatment gaps in dyslipidemia by initiating appropriate statin intensity early, using combination therapy when needed, and proactively assessing adherence.

Anne Cassity of the NCPA outlines the historic passage of federal pharmacy benefit manager (PBM) reform and explains how new Medicare Part D contracting standards could reshape reimbursement and oversight for community pharmacies.

Derek Webb and Dennis Williams discuss key global learnings from the FIP World Congress of Pharmacy, highlighting how pharmacists worldwide are leading proactive OTC allergy care and what practical strategies US community pharmacies can adopt.

MammaPrint genomic profiling guides personalized HR-positive breast cancer treatment, helping pharmacists and oncology teams reduce chemotherapy use while protecting outcomes.

Pharmacists can use collaborative practice agreements in neurology to manage multiple sclerosis medications, labs, and expand care beyond disease-modifying therapies.

Learn how pharmacists cut GLP-1 costs, streamline prior authorizations, guide safe switches, and bust social media myths for lasting adherence.

Ann Marie Navar, MD, PhD, explains how enlicitide’s sustained LDL-C lowering, favorable tolerability, and structured dosing may improve adherence and expand oral add-on options for patients not at goal on statins.

Pharmacists are critical in supporting GLP-1 therapy success through proactive expectation setting.

NCCN updates can guide pharmacists to tailor chemotherapy for HR+/HER2- breast cancer using MammaPrint and FLEX survival data.

The VESALIUS-CV trial demonstrates that adding evolocumab to maximally tolerated statin therapy significantly reduces major cardiovascular events in both high-risk primary and secondary prevention patients.

Ongoing variation in vaccine schedule implementation requires pharmacists and clinicians to collaborate closely, reinforce evidence-based care, and monitor vulnerable populations for gaps in immunization coverage.

Pharmacists play a vital role in countering GLP-1 misinformation.